Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Drug Profile

Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycin

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class Antibacterials; Macrolides; Phenazines; Rifamycins
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Multiple sclerosis
  • Preclinical Mycobacterial infections; Psoriasis; Type 1 diabetes mellitus
  • No development reported Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 13 Nov 2017 Redhill Biopharma plans a pivotal phase III trial for Mycobacterial infections (nontuberculous mycobacteria) in USA in the first half of 2018
  • 09 Nov 2017 RedHill Pharma completes enrolment in the phase III MAP US trial in Crohn's disease in USA, Europe, Canada, Israel, Australia and New Zealand (NCT01951326)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Israel (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top